Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
Key Highlights
- ➤ICOTYDE achieved ACR20 response in 58% versus 41% for placebo at Week 16
- ➤ICOTYDE achieved ACR50 response in 29% versus 16% for placebo at Week 16
- ➤ICOTYDE ACR20 response reached 69% by Week 24
- ➤ICOTYDE delivered clear or almost clear skin in 57% versus 14% for placebo
- ➤No new safety signals emerged through Week 24; ICOTYDE remains investigational for active PsA
Expert Statements
Joseph F. Merola, Rheumatologist, Dermatologist, President of the Psoriasis and Psoriatic Arthritis Multicenter Advancement Network, Co-President of the Group for Research in Psoriasis and Psoriatic Arthritis, and President of the Rheumatologic Dermatology Society
“The significant joint responses observed in this study show the exciting potential for ICOTYDE, a targeted oral peptide therapy, to open an entirely new chapter in treating psoriatic arthritis with an oral option”
Joseph F. Merola, Rheumatologist, Dermatologist, President of the Psoriasis and Psoriatic Arthritis Multicenter Advancement Network, Co-President of the Group for Research in Psoriasis and Psoriatic Arthritis, and President of the Rheumatologic Dermatology Society
“Effective management of psoriatic arthritis requires addressing both joint and skin disease, and patients continue to need treatment options that can provide meaningful improvement across both.”
David M. Lee, M.D., Ph.D., Global Immunology Therapeutic Area Head, Johnson & Johnson
“Many people living with psoriatic arthritis are still searching for treatments that can effectively address the full burden of their disease”
David M. Lee, M.D., Ph.D., Global Immunology Therapeutic Area Head, Johnson & Johnson
“These new findings underscore the potential of ICOTYDE to meaningfully improve outcomes in psoriatic arthritis and add to the growing body of evidence across psoriatic disease.”
Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide PR Newswire
* Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16 * ICOTYDE is a first-in-class IL-23R targeted oral peptide, demonstrating significant joint and skin improvements and a favorable safety profile in a once-daily pill NEW BRUNSWICK, N.J., Nov. 7, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive results from a Phase 3 study investigating ICOTYDE(®) (icotrokinra) in biologic-naïve adults with active psoriatic arthritis (PsA).(a,b )ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.(1) ICOTYDE met the primary endpoint, with 58% of patients achieving an American College of Rheumatology 20 (ACR20) response compared with 41% receiving placebo at Week 16.(2) Safety findings were consistent with the established safety profile of ICOTYDE, with no new safety signals identified. These results are being presented as a late-breaking poster at the American College of Rheumatology (ACR) Convergence 2026.
Get started
Create a free account to read the full story.